Benefits
Galactomannan fibre: the proposed satiety mechanism
Galactomannan is a viscous soluble fibre, and viscous fibres can slow gastric emptying and increase fullness. That effect is strongly dose-dependent: the human studies behind it used 5-50 g of carob fibre per day, or 2-4 g of glucomannan. Csat+ is roughly 20% galactomannan, so a capsule-sized serving supplies a small fraction of those amounts. No study has measured appetite, fullness or food intake in people taking Csat+.
Inositols: a small amount of a studied compound
Csat+ is specified to at least 5% inositols, and Pharmactive's published breakdown is mostly D-pinitol (about 4.7%) with only about 0.35% myo-inositol. The inositol supplements studied for insulin sensitivity and PCOS use myo-inositol at 2-4 g/day: one to two orders of magnitude more, and a different inositol. A 90-day trial in adults with prediabetes did lower HbA1c and fasting glucose, but it used another company's inositol-standardised carob liquid at 6.66 g/day, not Csat+.
α-Amylase inhibition: a laboratory finding
Carob water decoctions inhibit α-amylase and α-glucosidase in test-tube assays, although the strongest inhibition came from leaf and stem-bark preparations rather than the pod material used in supplements. Whether this happens in the human gut is unresolved, and the direct evidence is uncomfortable: when healthy volunteers drank a 50 g glucose solution with carob pulp fibre added, the 5 g and 10 g doses raised plasma glucose by 47% and 64% and serum insulin by about 20-25% compared with the glucose drink alone.
Blood lipids: dose-dependent and, in humans, mixed
Viscous fibres bind bile acids in the gut, and reviews of carob describe lipid lowering through that route plus effects in liver and fat tissue. The human record is narrower than that sounds. A study using 50 g/day of carob pulp fibre lowered post-meal triglycerides and free fatty acids but did not measure cholesterol at all; a six-week randomised trial of commercial carob syrup in 72 adults lowered total cholesterol by about 15 mg/dL and waist circumference by about 3.6 cm; and a 90-day placebo-controlled trial of a carob liquid concentrate found no change in total cholesterol or HDL, with LDL differing from placebo only because the placebo group's LDL rose. Total and LDL cholesterol fell in mice given Csat+. No lipid outcome has been measured in people taking Csat+.
Prebiotic fermentation: test-tube evidence
Csat+ is specified to at least 2% oligofructoses, and when it was incubated with human faecal bacteria in an anaerobic laboratory model it shifted microbial composition and raised short-chain fatty acid output compared with a control medium. That work was done in glassware. It did not measure appetite, body weight or any outcome in a person, and no study has shown a microbiome change in people taking Csat+.
Antioxidant activity: animal and laboratory data
Gallic acid is the main phenolic measured in carob pod, and Csat+ is specified to at least 0.1%. In mice fed a high-fat, high-sugar diet, Csat+ raised the expression of antioxidant enzymes and lowered inflammatory markers such as IL-6, TNFα and MCP-1 in liver, muscle, fat and aortic tissue. Those were animal experiments funded by the manufacturer, and oxidative stress markers have not been measured in people taking Csat+.
Standardisation and identity
Csat+ is made to a published specification, with galactomannan, inositols, gallic acid and oligofructoses each assayed, so one batch should resemble the next, which unstandardised carob powder cannot promise. The extraction process is covered by patent WO 2019/068466 A1, co-assigned to Pharmactive, the Spanish research council CSIC and the Universidad Autónoma de Madrid. Standardisation and a patent describe how an ingredient is made; neither is evidence that it works, and the NutraIngredients Awards 2020 shortlisting is a trade award, not a clinical result.
Mechanism of action
Viscous fiber gastric distension
Galactomannan from carob seed endosperm forms a viscous gel in the stomach, expanding to occupy volume and signaling fullness via mechanoreceptors in the gastric wall. The gel also slows gastric emptying — sustaining satiety over extended periods. Glucomannan from konjac works this way, but the trials establishing it used 2-4 g/day of purified fibre, far more galactomannan than a capsule of a 20%-standardised extract can carry.
IPG second-messenger insulin signaling
Inositols from carob support inositol phosphoglycan (IPG) second-messenger pathways that mediate insulin receptor signaling. Improved IPG signaling means cells respond better to circulating insulin, supporting glucose uptake and metabolic health. That pathway is established for myo-inositol at 2-4 g/day; the inositol fraction of Csat+ is mostly D-pinitol and is present in far smaller amounts.
α-Amylase enzymatic inhibition
Carob polyphenols inhibit both pancreatic and salivary α-amylase — the enzymes responsible for starch breakdown into absorbable monosaccharides. Slowing this conversion reduces post-prandial glucose spikes. This has been shown in test-tube assays of carob preparations, not in the human gut after a dose of Csat+.
Bile acid binding and cholesterol metabolism
Soluble fiber from carob binds bile acids in the gut, preventing their reabsorption and forcing the liver to synthesize new bile acids using circulating cholesterol. Enough viscous fibre can lower serum cholesterol this way, but the effect tracks the grams of fibre consumed and it has not been demonstrated at Csat+ doses.
Clinical trials
Two animal experiments, not human trials. C57BL/6J mice were fed a high-fat, high-sugar diet and given Csat+ at 4.8% of the diet by weight: de la Fuente-Fernández et al., Antioxidants 2020 (PMID 32326269, 26 weeks) and a 2022 follow-up combining Csat+ with two weeks of calorie reduction and aerobic training (PMID 36139877). Both were run by Universidad Autónoma de Madrid physiologists and funded by Pharmactive, which sells the ingredient.
Male C57BL/6J mice with diet-induced metabolic syndrome. No humans were studied.
In the 2020 study, Csat+ lowered blood glucose, HOMA-IR, insulin, total and LDL cholesterol and IL-6 in mice, prevented diet-induced hypertension and improved vascular function. In the 2022 study, Csat+ added to calorie restriction produced more body-weight loss and less epididymal fat than calorie restriction or exercise alone, and improved insulin sensitivity in liver and skeletal muscle. Neither study measured appetite directly, and results in mice eating the extract at 4.8% of their diet do not establish what a person taking a capsule will experience.
A 90-day randomised, double-blind, placebo-controlled trial (Pérez-Piñero et al., Nutrients 2026, PMID 42196981; registered NCT07379931). The product was a carob liquid concentrate standardised to inositols (15.5% D-pinitol, 165.2 mg/g total inositols) and taken as 6.66 g/day in two sachets before lunch and dinner. It was manufactured and funded by Planttech Biotechnology Spain S.L., a different company, and is not standardised to galactomannan. This is the closest human trial of a carob extract; it is not a trial of Csat+.
52 adults with confirmed prediabetes (25 active, 27 placebo), 27 men and 25 women, mean age 45.6 years, mean BMI about 28.
Against placebo, the carob concentrate lowered HbA1c (−0.29% versus −0.04%, p<0.001), fasting glucose, the glucose area under the curve during an oral glucose tolerance test (p=0.015), the insulin area under the curve (p=0.019) and the glucose peak (p=0.034), and improved HOMA-IR (p=0.038) and QUICKI (p=0.024). Fasting insulin fell within the active group but the difference from placebo was not significant (p=0.071). Body weight, BMI and fat mass did not change in either group, and neither did total cholesterol or HDL; LDL differed between groups (p=0.003) because it rose in the placebo group rather than falling on the active product. The product was well tolerated over 90 days with no adverse effects recorded.